Publications by authors named "Fumery M"
Modifying Our Environment to Improve Outcomes in Inflammatory Bowel Diseases?
United European Gastroenterol J
December 2024
Background & Aims: Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD). The aim of our study was to evaluate incident cancer rate (recurrence or new-onset cancer) in a cohort of patients with IBD with a history of breast cancer according to the subsequent IBD treatment provided.
Methods: A multicenter retrospective study included consecutive patients with IBD with prior breast cancer.
Background And Aims: Achieving deep remission, encompassing clinical, endoscopic, and biological remission, is the goal in managing Crohn's disease (CD). The role of histological remission remains unclear. This study aimed to examine the impact of histological inflammation on clinical relapse risk in CD and explore the relationship between histology, endoscopic scores, and biomarkers.
View Article and Find Full Text PDFArticle Synopsis
- The incidence of inflammatory bowel disease (IBD) in Northern France was studied over a 30-year period, revealing 22,879 new cases, with Crohn's disease (CD) and ulcerative colitis (UC) making up the majority.
- The incidence rates for both CD and UC increased significantly over the years, particularly in children and young adults, indicating a rising trend in these demographics.
- The findings suggest ongoing environmental factors contributing to the increasing prevalence of IBD, especially among women with UC, with projections indicating that nearly 0.6% of the population will have IBD by 2030.
Article Synopsis
- The study focuses on SB5, an adalimumab biosimilar approved in Europe in 2017, and aims to gather real-world data on its usage and effectiveness in patients with various immune-mediated inflammatory diseases (IMIDs).
- Researchers analyzed clinical and healthcare claims data from the French national healthcare database to assess patient persistence on SB5 after 12 months.
- Among 911 patients treated with SB5, notable remission rates were observed at the 12-month mark, particularly in naïve patients, across various conditions such as rheumatoid arthritis and Crohn's disease, with all showing significant improvement from baseline.
Background: Mucosal healing (MH) is an established treatment goal in inflammatory bowel disease (IBD). However, various definitions of MH exist. We aimed to identify how MH is defined in randomized controlled trials (RCTs) in ulcerative colitis (UC) and Crohn's disease (CD).
View Article and Find Full Text PDFArticle Synopsis
- Patients with inflammatory bowel disease (IBD), specifically children with Crohn's disease (CD) and ulcerative colitis (UC), have a higher risk of thromboembolic events (TE), but more information is needed regarding the incidence and risk factors for better preventative care.
- The study followed 1,344 pediatric patients from 1988 to 2013, finding very few instances of arterial (ATE) and venous thromboembolic events (VTE) during the follow-up period, with VTE being more frequent in specific circumstances.
- Overall, while the risk of TE in this population is low, it was significantly linked to periods of active disease, post-surgery conditions, and hospitalization, while treatment with
Article Synopsis
- * Researchers analyzed data from 88 patients with 96 strictures over nearly 30 years, noting that a significant percentage of the strictures were nonpassable and symptomatic, leading to surgical interventions for many.
- * Ultimately, 8% of patients were diagnosed with cancer at the stricture site, often at the same time as the stricture; however, no patients were reported to have malignant strictures after one year of follow-up.
Background: Specific studies on the impact of ulcerative colitis (UC) and bowel urgency (BU) on disability and quality of life (QoL) of patients on advanced therapies are missing.
Methods: Clinical and therapeutic management data were collected by Gastroenterologists from adult patients with UC treated with advanced therapies. Patients reported outcomes on QoL were collected using patient-reported questionnaires.
Article Synopsis
- Recto-colic graft-versus-host disease (GVHD) is a common post-transplant complication, and the study aimed to establish histological markers for diagnosis and prognosis.
- A total of 119 patients were reviewed; 67 had confirmed GVHD, identified by higher counts of apoptotic bodies (AB) in biopsies, with significant differences in staining methods.
- A diagnostic threshold of 4 AB per 10 crypts signals GVHD, while more than 8 AB indicates a poor prognosis, with additional findings of eosinophilic cell-lining in glands suggesting further diagnostic potential.
The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID) was founded in Paris in 1983 by Professor R Modigliani and colleagues. From the beginning, the aim of this international (France, Belgium and Switzerland), multicentre, French-speaking group was to address clinical questions raised by patients or physicians in their daily practice or the inflammatory bowel diseases community, by focusing on clinical research on treatments through randomised controlled trials, prospective cohorts and cross-sectional studies, quantifying the severity of various facets of the disease when necessary for these studies. This approach very innovative has contributed to the advancement of knowledge in inflammatory bowel diseases by publishing more than 120 original articles in peer-reviewed journals throughout the GETAID 40-year history, most of them in top publications in gastroenterology and hepatology journals.
View Article and Find Full Text PDFEpidemiological and translational data increasingly implicate environmental pollutants in inflammatory bowel disease (IBD). Indeed, the global incidence of IBD has been rising, particularly in developing countries, in parallel with the increased use of chemicals and synthetic materials in daily life and escalating pollution levels. Recent nationwide and ecological studies have reported associations between agricultural pesticides and IBD, particularly Crohn's disease.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted with 941 IBD patients to assess their satisfaction with different adalimumab preparations, including biosimilars and the original brand, Humira.
- The average satisfaction rating was 8.5 out of 10, with the highest satisfaction observed for Humira and its biosimilars like Hulio and Amgevita, where scores were notably above 8.5.
- Injection site reactions were reported by 31.8% of patients, and a portion of those previously treated with another adalimumab had discontinued due to side effects; overall, patient satisfaction remained high despite these issues.
Background: The development of noninvasive markers to assess mucosal healing in ulcerative colitis (UC) is essential in the treat-to-target era. The aim of this study was to evaluate the performance of intestinal ultrasound (IUS), fecal calprotectin (FC), and their combination to assess mucosal healing in UC patients.
Methods: All consecutive patients between January 2021 and September 2022 with UC who underwent a complete colonoscopy and IUS and/or an FC test within 4 weeks were included in a prospective cohort.
Introduction: Inflammatory bowel diseases (IBD) are frequently diagnosed between the ages of 20 and 40, i.e. the most fertile period for women.
View Article and Find Full Text PDFIntroduction: Endoscopy is still the gold, standard for assessing disease activity in Crohn's disease (CD). Its invasiveness, poor acceptability, and cost limit its use in the era of tight control and treat-to-target management. Fecal calprotectin (FC) and intestinal ultrasound (IUS) are non-invasive alternatives to colonoscopy to assess disease activity.
View Article and Find Full Text PDFFactors associated with decreased ovarian reserve in Crohn's disease: A systematic review and meta-analysis.
Acta Obstet Gynecol Scand
September 2024
Introduction: It is still unclear whether Crohn's disease (CD) might be associated with diminished ovarian reserve (OvR) and factors influencing anti-Mullerian hormone (AMH) levels in CD are poorly known.
Material And Methods: We conducted a comprehensive literature search of multiple electronic databases from inception to June 2022 to identify all studies reporting AMH levels or factors associated with diminished OvR in patients with CD.
Results: Of the 48 studies identified in our search, eight (including 418 patients with CD) were finally included.
Background: Both vedolizumab and ustekinumab can be considered for the treatment of ulcerative colitis [UC], but head-to-head trials are lacking.
Aim: We aimed to compare the effectiveness of vedolizumab and ustekinumab after anti-tumour necrosis factor [anti-TNF] failure in UC patients.
Patients And Methods: In this multicentre study, we included consecutive adult patients with UC, with partial Mayo score >2 and prior anti-TNF exposure, treated with vedolizumab or ustekinumab between January 2019 and August 2022.
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study.
Clin Gastroenterol Hepatol
December 2024
Background & Aims: The aim of this study was to assess the long-term effectiveness and safety of risankizumab maintenance treatment in a large real-world cohort of patients with Crohn's Disease (CD).
Methods: From May 2021 to August 2023, all consecutive patients with CD treated with risankizumab in 25 GETAID centers have been retrospectively included. The primary endpoint was steroid-free clinical remission (Harvey Bradshaw Index [HBI] <5) at 52 weeks.
Background: Acute gastrointestinal bleeding (AGIB) is common in older patients but the use of iron in this context remains understudied.
Aims: This study aimed to evaluate prospectively the efficacy of ferric carboxymaltose to treat anaemia in older patients after AGIB.
Methods: This randomised double-blinded placebo-controlled clinical trial was conducted in 10 French centres.
Background And Aims: Epidemiological data regarding inflammatory bowel disease [IBD] are lacking, in particular for occupationally exposed populations. We investigated whether, among the entire French farm manager [FM] workforce, certain agricultural activities are more strongly associated with IBD than others.
Methods: Nationwide, population-based, insurance claims and electronic health records from all FMs who worked at least once over the period 2002-2016 were used [n = 1 088 561, 69% males].
Has the time come for a systematic top-down approach in Crohn's disease?
Lancet Gastroenterol Hepatol
May 2024
Background: Data on infliximab efficacy in bio-exposed patients with ulcerative colitis (UC) are limited.
Aims: To evaluate infliximab effectiveness and its predictors in UC patients with prior exposure to subcutaneous (SC) anti-TNF agent.
Methods: In this multicenter retrospective study (8 centers), we included all consecutive UC patients with prior exposure to subcutaneous anti-TNF, starting infliximab for symptomatic UC, excluding acute severe colitis.
Introduction: Chronic inflammatory bowel disease (IBD) is thought to increase the risk of high-grade histological intraepithelial lesions (HGIL) and cervical cancer. The risk factors for developing these lesions are poorly understood.
Materials And Methods: This is a single-center retrospective case-control study including IBD patients followed at our University Hospital Center from 2011 to 2021 who presented with HGIL or cervical cancer.